Polypharmacy among older Australians, 2006-2017: a population-based study

被引:126
作者
Page, Amy T. [1 ,2 ,3 ]
Falster, Michael O. [4 ]
Litchfield, Melisa [4 ]
Pearson, Sallie-Anne [4 ,5 ]
Etherton-Beer, Christopher [6 ,7 ]
机构
[1] Alfred Hlth, Melbourne, Vic, Australia
[2] Monash Univ, Ctr Med Use & Safety, Melbourne, Vic, Australia
[3] Univ Western Australia, Ctr Optimisat Med, Perth, WA, Australia
[4] UNSW Australia, Ctr Big Data Res Hlth, Sydney, NSW, Australia
[5] Univ Sydney, Menzies Ctr Hlth Policy, Sydney, NSW, Australia
[6] Univ Western Australia, WA Ctr Hlth & Ageing, Perth, WA, Australia
[7] Royal Perth Hosp, Perth, WA, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
Prescribing; Prescription drugs; Chronic disease; Aged; MEDICATION ADHERENCE; QUALITY USE; MEDICINES; PEOPLE; INTERVENTIONS; OUTCOMES; CARE; MEN;
D O I
10.5694/mja2.50244
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo estimate the prevalence of polypharmacy among Australians aged 70 years or more, 2006-2017. Design, setting and participantsAnalysis of a random 10% sample of Pharmaceutical Benefits Scheme (PBS) data for people aged 70 or more who were dispensed PBS-listed medicines between 1 January 2006 and 31 December 2017. Main outcome measuresPrevalence of continuous polypharmacy (five or more unique medicines dispensed during both 1 April - 30 June and 1 October - 31 December in a calendar year) among older Australians, and the estimated number of people affected in 2017; changes in prevalence of continuous polypharmacy among older concessional beneficiaries, 2006-2017. ResultsIn 2017, 36.1% of older Australians were affected by continuous polypharmacy, or an estimated 935240 people. Rates of polypharmacy were higher among women than men (36.6% v 35.4%) and were highest among those aged 80-84 years (43.9%) or 85-89 years (46.0%). The prevalence of polypharmacy among PBS concessional beneficiaries aged 70 or more increased by 9% during 2006-2017 (from 33.2% to 36.2%), but the number of people affected increased by 52% (from 543950 to 828950). ConclusionsThe prevalence of polypharmacy among older Australians is relatively high, affecting almost one million older people, and the number is increasing as the population ages. Our estimates are probably low, as we could not take over-the-counter or complementary medicines or private prescriptions into account. Polypharmacy can be appropriate, but there is substantial evidence for its potential harm and the importance of rationalising unnecessary medicines, particularly in older people.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 26 条
[1]   Methods for evaluation of medication adherence and persistence using automated databases [J].
Andrade, Susan E. ;
Kahler, Kristijan H. ;
Frech, Feride ;
Chan, K. Arnold .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (08) :565-574
[2]  
Australian Bureau of Statistics, Q POP EST ERP STAT T
[3]  
Australian Department of Health, PBS ACC SUST PACK IN
[4]  
Australian Department of Health, DISC PBS PAT COP
[5]  
Australian Department of Human Services, PHARM BEN SCHED GROU
[6]  
Australian Department of Human Services, 2016, PROP LIST CHANG OTC
[7]   Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence [J].
Balu, Sanjeev ;
Simko, Robert J. ;
Quimbo, Ralph M. ;
Cziraky, Mark J. .
CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (11) :2765-2775
[8]   Quality use of medicines and health outcomes among a cohort of community dwelling older men: an observational study [J].
Beer, Christopher ;
Hyde, Zoe ;
Almeida, Osvaldo P. ;
Norman, Paul ;
Hankey, Graeme J. ;
Yeap, Bu B. ;
Flicker, Leon .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 71 (04) :592-599
[9]  
Elliott RA., 2016, Drugs - Real World Outcomes, V3, P13, DOI [10.1007/s40801-016-0065-6, DOI 10.1007/S40801-016-0065-6]
[10]   Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database [J].
Fincke, BG ;
Snyder, K ;
Cantillon, C ;
Gaehde, S ;
Standring, P ;
Fiore, L ;
Brophy, M ;
Gagnon, DR .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (02) :121-128